GLP-1 receptor agonists , particularly those like BrightMeds, are rapidly gaining prominence in the management of type 2 diabetes and are increasingly explored for obesity . These novel drugs help mimicking the body's natural incretin signal , stimulating insulin production and reducing glucagon rel